Gilead opting against IDE397 is still good news for Ideaya.
ApexOnco Front Page
Recent articles
Progression-free and overall survival data from Companion-002 are due this quarter.
The fate of the group’s previous lead project, the Amgen-partnered CX-904, looks uncertain.
Olema will soon enter the clinic, and Pfizer could shortly be in phase 3.
A new phase 3 study will test Anktiva in PD-(L)1-relapsed lung cancer.
Subcutaneous Opdivo joins Tecentriq Hybreza to round out 2024.
The synthetic lethality specialist licenses in its second ADC in six months.
Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.
